[go: up one dir, main page]

MX9804459A - Procedimiento para el diagnostico y terapia de epitelioma. - Google Patents

Procedimiento para el diagnostico y terapia de epitelioma.

Info

Publication number
MX9804459A
MX9804459A MX9804459A MX9804459A MX9804459A MX 9804459 A MX9804459 A MX 9804459A MX 9804459 A MX9804459 A MX 9804459A MX 9804459 A MX9804459 A MX 9804459A MX 9804459 A MX9804459 A MX 9804459A
Authority
MX
Mexico
Prior art keywords
epithelioma
diagnosis
therapy
procedure
target
Prior art date
Application number
MX9804459A
Other languages
English (en)
Inventor
Karl-Heinz Heider
Gunther Adolf
Elinborg Ostermann
Erik Patzelt
Marlies Sproll
Original Assignee
Boehringer Ingelheim Int
Karlsruhe Forschzent
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19545472A external-priority patent/DE19545472A1/de
Application filed by Boehringer Ingelheim Int, Karlsruhe Forschzent filed Critical Boehringer Ingelheim Int
Publication of MX9804459A publication Critical patent/MX9804459A/es

Links

Classifications

    • G01N33/575—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70585—CD44
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invencion se refiere a un procedimiento para el diagnostico y la terapia de epitelioma, que se basa en la expresion del exon variante v6 del gen CD44, como blanco u objetivo molecular. En una forma de realizacion preferida, se utilizan moléculas de anticuerpos específicos a v6, en especial el anticuerpo monoclonal BIWA-1- (VFF-18).
MX9804459A 1995-12-06 1998-06-04 Procedimiento para el diagnostico y terapia de epitelioma. MX9804459A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19545472A DE19545472A1 (de) 1995-12-06 1995-12-06 Verfahren zur Diagnose und Therapie von Plattenepithelkarzinomen
DE19615074 1996-04-17

Publications (1)

Publication Number Publication Date
MX9804459A true MX9804459A (es) 1998-09-30

Family

ID=26020988

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9804459A MX9804459A (es) 1995-12-06 1998-06-04 Procedimiento para el diagnostico y terapia de epitelioma.

Country Status (25)

Country Link
EP (1) EP0865609B1 (es)
JP (1) JP2000502067A (es)
KR (1) KR100473824B1 (es)
CN (1) CN1151377C (es)
AR (1) AR004360A1 (es)
AT (1) ATE235056T1 (es)
AU (1) AU726704B2 (es)
BG (1) BG62985B1 (es)
BR (1) BR9611901A (es)
CA (1) CA2239709A1 (es)
CO (1) CO4520233A1 (es)
CZ (1) CZ174198A3 (es)
DE (1) DE59610248D1 (es)
DK (1) DK0865609T3 (es)
EE (1) EE03783B1 (es)
ES (1) ES2190484T3 (es)
MX (1) MX9804459A (es)
NO (1) NO319903B1 (es)
NZ (1) NZ324314A (es)
PL (1) PL184521B1 (es)
PT (1) PT865609E (es)
SK (1) SK284378B6 (es)
TR (1) TR199801027T2 (es)
UY (1) UY24389A1 (es)
WO (1) WO1997021104A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7947496B2 (en) * 1999-10-08 2011-05-24 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7189397B2 (en) * 1999-10-08 2007-03-13 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US20050100542A1 (en) * 1999-10-08 2005-05-12 Young David S. Cytotoxicity mediation of cells evidencing surface expression of CD44
BR0210905A (pt) * 2001-05-18 2004-06-08 Boehringer Ingelheim Int Anticorpos especìficos para cd44v6
US20030103985A1 (en) 2001-05-18 2003-06-05 Boehringer Ingelheim International Gmbh Cytotoxic CD44 antibody immunoconjugates
US6972324B2 (en) 2001-05-18 2005-12-06 Boehringer Ingelheim Pharmaceuticals, Inc. Antibodies specific for CD44v6
EP1258255A1 (en) * 2001-05-18 2002-11-20 Boehringer Ingelheim International GmbH Conjugates of an antibody to CD44 and a maytansinoid
EP1391213A1 (en) * 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
EP1417974A1 (en) * 2002-11-08 2004-05-12 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and radiotherapy
MY157532A (en) * 2010-02-04 2016-06-15 Univ Miami A monoclonal antibody to cd44 for use in the treatment of head and neck squamous cell carcinoma
US9218450B2 (en) * 2012-11-29 2015-12-22 Roche Molecular Systems, Inc. Accurate and fast mapping of reads to genome
JP2021519608A (ja) * 2018-02-22 2021-08-12 マルティチュード・インコーポレーテッド 治療抗体およびその使用
EP4532019A2 (en) 2022-05-25 2025-04-09 Akiram Therapeutics AB Anti-cd44v6 antibodies and their use to treat cd44v6 overexpressing cancers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2165461A1 (en) * 1993-06-18 1995-01-05 Sirpa Jalkanen Compositions and diagnostic methods using monoclonal antibodies against cd44v6
EP0767378A1 (de) * 1993-06-22 1997-04-09 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Verfahren zur Diagnose und Analyse von Magenkarzinomen
DE4326573A1 (de) * 1993-08-07 1995-02-23 Boehringer Ingelheim Int Durch Exon v5 des CD44-Gens kodierte Polypeptide als Targets für Immuntherapie und Immunszintigraphie von Tumoren
UA58482C2 (uk) * 1994-06-08 2003-08-15 Бьорінгер Інгельхайм Інтернаціональ Гмбх Моноклональне антитіло vff-18 проти сd44v6 і його фрагменти

Also Published As

Publication number Publication date
CN1151377C (zh) 2004-05-26
EE03783B1 (et) 2002-06-17
EP0865609B1 (de) 2003-03-19
NZ324314A (en) 2000-02-28
CO4520233A1 (es) 1997-10-15
KR19990071952A (ko) 1999-09-27
ATE235056T1 (de) 2003-04-15
SK284378B6 (sk) 2005-02-04
AU726704B2 (en) 2000-11-16
NO982588L (no) 1998-08-05
NO319903B1 (no) 2005-09-26
EE9800164A (et) 1998-12-15
DK0865609T3 (da) 2003-06-23
UY24389A1 (es) 2001-10-25
DE59610248D1 (de) 2003-04-24
BR9611901A (pt) 1999-03-02
AU1177397A (en) 1997-06-27
WO1997021104A1 (de) 1997-06-12
ES2190484T3 (es) 2003-08-01
JP2000502067A (ja) 2000-02-22
PL327066A1 (en) 1998-11-23
PT865609E (pt) 2003-08-29
NO982588D0 (no) 1998-06-05
KR100473824B1 (ko) 2005-09-30
HK1011560A1 (en) 1999-07-16
EP0865609A1 (de) 1998-09-23
CN1207811A (zh) 1999-02-10
CA2239709A1 (en) 1997-06-12
PL184521B1 (pl) 2002-11-29
BG102513A (en) 1999-02-26
SK73698A3 (en) 1999-01-11
CZ174198A3 (cs) 1999-02-17
AR004360A1 (es) 1998-11-04
TR199801027T2 (xx) 1998-10-21
BG62985B1 (bg) 2000-12-29

Similar Documents

Publication Publication Date Title
MX9804459A (es) Procedimiento para el diagnostico y terapia de epitelioma.
CY1107294T1 (el) Τοπικη συνθεση η οποια περιεχει τουλαχιστον μια βιταμινη d ή ενα αναλογο της βιταμινης d και τουλαχιστον ενα κορτικοστεροειδες
BR112022008817A2 (pt) Terapias combinadas para tratamento de câncer
TR200000927T2 (tr) Prostaglandin agonistleri ve kemik bozukluklarının tedavisi
NO963860L (no) Isoprenyl-transferase-inhibitorer
CO4600637A1 (es) Compuestos para inmunoterapia e inmunodiagnosis del cancer de prostata
ES2145451T3 (es) Secuencia de dna y proteina de cancer de mamas codificada especifica para mamas.
MX9304329A (es) Molecula de arn enzimatica y celula que la incluye, para el tratamiento de enfermedades en animales y humanos.
ES2191018T3 (es) Procedimiento para detectar micrometastasis de cancer de prostata.
ES2172303T3 (es) Agentes terapeuticos obtenidos por catalisis enzimatica.
DK0680517T3 (da) Fremgangsmåde og diagnostiske sæt til bestemmelseaf en forbindelses toksicitet under anvendelse afstress-promotorer fra pat
EP1004022A4 (en) METHODS AND COMPOSITIONS TO OVERCOME RESISTANCE TO BIO- AND CHEMOTHERAPY
TR200002731T2 (tr) Proteolitik antikorların indüktör ve inhibitörlerinin tanımlanması, kompozisyonları ve kullanımları için metotlar
NO990522D0 (no) Anvendelse av <beta>-ark mimetika som protease- og kinaseinhibatorer av transkripsjonsfaktorer
ATE466595T1 (de) Verbindungen und methoden für das downregulating der effekte von tgf-beta
CO2022010337A2 (es) Anticuerpos monoclonales anti-sirpα y usos de los mismos
MXPA03000316A (es) Reactivos y metodos para la identificacion de agentes de enlace.
PT862622E (pt) Metodo de rastreio para compostos que interagem com proteina cinase rac
BR112022016304A2 (pt) Métodos de prognóstico terapêutico.
ATE226254T1 (de) Reagenz zur behandlung von arthritischen zustaenden
AR011607A1 (es) Polipeptido aislado que codifica un supresor tumoral ts10q23.3, anticuerpo monoclonal , celula de hibridoma, antisuero policlonal, acido nucleico yoligonucleotido aislados. metodo para diagnosticar cancer, alterar el fenotipo de una celula tumoral, determinar el estadio de un cancer, pronosticar
ES2061521T3 (es) Proteinas con actividad glutation-s-transferasa, secuencias de adn, anticuerpos, poxvirus y medicamentos para la prevencion de la equistosomiasis.
PT1267915E (pt) Metodos para tratar doencas com proteina c activada
AR004093A1 (es) El uso de una proteina derivada de una quimioquina de mamifero y un medicamento util para movilizar celulas tronco hematopoyeticas.
ES2178677T3 (es) Metodo para identificar compuestos, util para tratar enfermedades autoinmunes.

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees